
|Articles|February 4, 2013
FDA Challenges Stem Cell Companies As Patients Run Out Of Time
Advertisement
Americans seeking stem cell replacement therapy hope the process can heal them of myriad diseases, and a 2011 report by the Baker Institute estimated the industry could bring in $16 billion in revenue by 2020.
But the Food and Drug Administration has expressed concerns. The agency sued to stop treatments at a Regenerative Sciences clinic in Colorado and closed the lab of another company, Celltex Therapeutics, in Texas.
Read the full story:
Source: NPR
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
5













































